Abstract. Our understanding of the molecular mechanisms of renal magnesium (Mg 2+ ) handling has greatly enhanced over recent years. This review highlights the regulatory factors controlling Mg 2+ homeostasis through its effects on the epithelial Mg 2+ channel TRPM6 (Transient Receptor Potential Melastatin subtype 6), the gatekeeper of the body's Mg 2+ balance. Drug treatment, acid-base status, and several hormones have been shown to regulate TRPM6 expression, while its channel activity is modified by intracellular Mg 2+ , pH, and ATP. Recently, epidermal growth factor (EGF) and estrogen have been implicated as magnesiotropic hormones. The stimulation of the EGF receptor (EGFR) leads to an intracellular cascade involving Rac1 that promotes trafficking of TRPM6 to the plasma membrane. Furthermore, long-term EGF treatment upregulates the expression of TRPM6. Estrogen has also been shown to stimulate TRPM6 activity upon short-term treatment, next to its long-term regulatory effect on TRPM6 transcription. TRPM6, and its closest homologue TRPM7, are composed of a Mg 2+ -permeable channel fused to an α-kinase domain. In the intracellular compartment, the receptor for activated C-kinase (RACK1), the repressor for estrogen receptor activity (REA), and ATP were identified as negative modulators of TRPM6 activity through its α-kinase domain. Therefore, the α-kinase domain acts as an indirect player involved in Mg 2+ homeostasis by its feedback function in the TRPM6-mediated Mg 2+ influx. excretion and is, therefore, the predominant target of specific regulatory actions. Although Mg 2+ handling has been the focus of research for decades, only recent studies have disclosed the molecular players involved in this process. Most of our understanding derives from studies of rare inherited forms of hypomagnesemia due to renal Mg 2+ wasting [7] [8] [9] .
Renal Mg
2+ handling Mg 2+ is essential for the energy metabolism of the body. It is an important mineral for neurotransmission, muscular relaxation, bone stability, and other cellular functions [1] . As a consequence, profound Mg 2+ deficiency causes tetany, seizures, and cardiac arrhythmias [2] . The Mg 2+ balance is tightly controlled by the dynamic action of intestinal absorption, exchange with bone, and renal excretion. Daily, 2g of Mg 2+ is freely filtered by the glomeruli. The majority of Mg 2+ is reabsorbed in the proximal tubule (~20%) and the thick ascending limb (TAL) of Henle's loop (~70%) via paracellular pathways [3, 4] . Here, the driving force of Mg 2+ reabsorption is the positive transluminal epithelial voltage generated by potassium (K + ) recycling across the apical membrane [5] . The remaining 10% of filtered Mg 2+ is reabsorbed in the distal convoluted tubule (DCT) by an active transcellular mechanism [6] (figure 1). This latter process defines the final urinary Mg 2+ excretion and is, therefore, the predominant target of specific regulatory actions. Although Mg 2+ handling has been the focus of research for decades, only recent studies have disclosed the molecular players involved in this process. Most of our understanding derives from studies of rare inherited forms of hypomagnesemia due to renal Mg 2+ wasting [7] [8] [9] .
TRPM6
A key molecule involved in Mg 2+ handling is the Transient Receptor Potential Melastatin subtype 6 (TRPM6). Mutations of this gene have been associated with the rare monogenetic disorder hypomagnesemia with secondary hypocalcemia (HSH) [8, 9] . The TRPM6 gene contains 39 exons encoding a protein of 2,022 amino acids [8] [9] [10] . TRPM6 shares approximately 50% sequence homology with TRPM7. These channels are composed of six membrane-spanning domains with a pore region between the fifth and sixth segment, and large intracellular amino (N) and carboxyl (C) termini. Furthermore, they are thought to form functional homotetramers or heterotetramers, which influence their channel characteristics [11, 12] . TRPM6 functions as a divalent cation channel and it has a higher affinity for Mg 2+ than for Ca 2+ [10] . Its channel activity is tightly regulated by intracellular Mg 2+ levels ([Mg   2+ ] i ) and inhibited by ruthenium red in a voltagedependent manner [10] . Furthermore, micromolar levels of 2-aminoethoxydeiphenyl borate (2-APB) can increase TRPM6 currents [12] . In addition, Li et al. [12, 13] demonstrated that TRPM6 inward currents significantly enhanced upon extracellular acidification, which is linked to specific residues in the TRPM6 pore region. Together with its Mg 2+ selectivity and sensitivity, TRPM6 has a restricted localization pattern along the luminal membranes of the colon and DCT, supporting a central role in active Mg 2+ (re)absorption [10] .
Regulation by its α-kinase domain TRPM6 and TRPM7 are unique by combining an ion channel with a fused α-kinase domain [14, 15] . While it has previously been shown that this catalytic domain is not essential for channel activity, recent studies have revealed an indirect regulatory role in the modulation of channel functioning [16] [17] [18] . In this line, RACK1, receptor for activated C-kinase 1, has been identified as the first TRPM6-associated J. VAN DER WIJST, ET AL. -permeable channel TRPM6. It outlines the molecular components involved in the regulation of TRPM6. Estrogen, acid-base status, tacrolimus and cyclosporin A regulate TRPM6 expression. Acidic extracellular pH was shown to increase divalent permeability of TRPM6. Furthermore, intracellular Mg 2+ inhibits TRPM6 channel activity. Other intracellular factors identified as modulators of TRPM6 channel activity were RACK1, REA, and ATP. They exert their effects through the fused α-kinase domain. EGF and estrogen function as magnesiotropic hormones stimulating TRPM6 activity.
partner. This protein interacts with the α-kinase domain thereby inhibiting TRPM6 channel activity (figure 1). The inhibitory effect of RACK1 was shown to be dependent on autophosphorylation of a threonine residue (T1851) in the α-kinase domain. Moreover, the autophosphorylation state influences the Mg 2+ -dependent inhibition of TRPM6 activity [16] . These data suggest a novel feedback mechanism of TRPM6-mediated Mg 2+ influx via autophosphorylation of the residue T1851, which activates the inhibitory effect of RACK1, thereby preventing Mg 2+ overload during active Mg 2+ reabsorption. So, the α-kinase domain may function as an intracellular Mg 2+ sensor, indirectly regulating channel activity via RACK1. Interestingly, PKC modulates the RACK1-dependent regulation of channel activity by dissociating the binding between RACK1 and the α-kinase domain [16] . Recently, more studies revealed phosphorylation targets of the α-kinase domain. TRPM6 and TRPM7 have been shown to share exogenous phosphorylation substrates as myosin IIA, IIB, and IIC [19] . Furthermore, Clark et al. [20] showed that the C-terminus of TRPM7 undergoes massive autophosphorylation, thereby increasing the rate of substrate phosphorylation [21] . The TRPM7 autophosphorylation has been mapped to a serine/ threonine-rich region close to the α-kinase domain. Despite the lack of sequence conservation, the TRPM6 α-kinase activity is regulated in a comparable fashion [20] .
Recently, a new TRPM6-interacting protein, a repressor of estrogen receptor activity (REA), has been described [22] . REA binds to the 6 th , 7 th , and 8 th β-sheets in the α-kinase domain, which is the same region as for RACK1. Most amino acids in this area are located on the peripheral region of the tertiary structure, which facilitates the interaction with regulatory proteins. REA inhibits TRPM6 channel activity in an α-kinase activity-dependent manner, since REA has no functional effect on the TRPM6 phosphotransferase-deficient mutant (K1804R) [22] . However, we demonstrated that REA is not a phosphorylation target of TRPM6, nor was TRPM6 autophosphorylation affected by REA. So, these data suggest another indirect regulation of TRPM6 activity, independent of autophosphorylation, but reliant on TRPM6 α-kinase activity. Taken together, REA acts as another negative modulator involved in renal Mg 2+ handling via regulating the TRPM6-mediated Mg 2+ -influx. Next to the associated proteins, ATP was found as a regulatory factor of the α-kinase domain [23] . The functional role of ATP and the α-kinase domain in regulating TRPM6/TRPM7 channel activity is controversial [23] [24] [25] [26] [27] . It has been suggested that Mg 2+ -ATP acts as a source of Mg 2+ to decrease channel activity, rather than inhibition by ATP itself [24] . On the other hand, it was concluded that ATP-dependent regulation of TRPM7 is mediated via a nucleotide-binding site in the α-kinase domain that acts synergistically with a Mg 2+ -binding site outside this domain [18, 27] . Interestingly, a recent study demonstrated that intracellular ATP can regulate TRPM6 channel activity via its α-kinase domain [23] . By binding to a conserved ATP-binding pocket in this domain, TRPM6-mediated currents are inhibited in a dose-dependent manner by Na + -ATP and Mg 2+ -ATP [23] . Mutation of a conserved residue (G 1955 D) in the putative motif eradicated the inhibitory ATP action, whereas this effect remained preserved in the TRPM6 K1804R mutant. The inhibition was specific for ATP as the effect could not be mimicked by GTP or CTP. Furthermore, strong Mg 2+ chelators like EDTA were used to demonstrate that the inhibitory effect is not due to the release of Mg 2+ from Mg 2+ -ATP [23] . These results indicate another regulatory mechanism of the α-kinase domain via the effect of intracellular ATP on TRPM6 channel activity independent of α-kinase activity [23] .
Hormonal regulation
Recently, genetic screening of two Dutch sisters with isolated autosomal recessive hypomagnesmia (IRH) led to the discovery of the first magnesiotropic hormone [7] . IRH is due to a mutation in the gene encoding the EGF precursor protein pro-EGF, which is expressed in DCT together with TRPM6. Physiologically, pro-EGF is sorted to both apical and basolateral membranes where it is cleaved by extracellular proteases into the active molecule EGF [7, 28] . It is suggested that P1070L, in the cytoplasmic domain, predominantly impairs the release of the hormone to the basolateral site. This disturbs the stimulatory effect of EGF on TRPM6 channel activity and leads to renal Mg 2+ wasting [7] . Normally, EGF will activate the basolateral EGF receptor (EGFR) following an intracellular signaling cascade to increase TRPM6 surface expression [29] . This signaling involves both the Src family of tyrosine kinases and the downstream effector Rac1 (figure 1). Using fluorescence recovery after photo bleaching, we demonstrated that activation of Rac1 increased the mobility of TRPM6 and a constitutively active mutant of Rac1 mimicked the stimulatory action of EGF on TRPM6 mobility and activity [29] . Another study reported that EGF increased the phosphorylation of ERK1/2, leading to upregulation of TRPM6 expression and Mg 2+ influx, which results in an increase in cell proliferation [30] . Supporting these studies was the observation that patients treated with the anticancer agent cetuximab, an EGFR-specific monoclonal antibody, develop hypomagnesemia [7, 31] . Indeed, pre-incubation with cetuximab abolished the stimulatory effect of EGF on TRPM6 channel activity. Taken together, these recent studies highlight an important role for EGFR signaling in the maintenance of Mg 2+ homeostasis with TRPM6 as a critical player. It would be interesting to investigate the effect of other blocking antibodies and antagonists of the EGFR on Mg 2+ balance in general and in particular on TRPM6 activity.
Estrogen has also been suggested as magnesiotropic hormone, since clinical studies have shown that the hypermagnesiuria in postmenopausal women significantly reduced after estrogen therapy [32, 33] . In addition, Groenestege et al. [34] demonstrated that the renal TRPM6 mRNA level was decreased in ovariectomized rats, which could be restored by supplementation with 17β-estradiol. This effect can be explained by enhanced transcriptional activity or mRNA stabilization of TRPM6. Thus far, detailed analysis has not resulted in estrogen-responsive elements in the putative promoter site of TRPM6. Next to the classic transcriptional pathway, accumulating evidence also suggests rapid estrogen effects that occur within minutes via a non-transcriptional route [35] [36] [37] Interestingly, a recent study revealed a rapid stimulatory effect of 17β-estradiol on TRPM6 [22] . Treatment with 17β-estradiol disassociated the binding between REA and the TRPM6 α-kinase domain, thereby attenuating its inhibitory effect on TRPM6 channel activity. In agreement with this, 17β-estradiol significantly stimulated TRPM6 activity, without affecting the plasma membrane trafficking [22] . Estrogen has the ability to facilitate rapid membrane-initiated signaling cascades through activation of plasma membrane-associated receptors, such as the recently discovered G protein-coupled receptor 30 (GPCR30) [38] . In addition, it was demonstrated that the classical estrogen receptor alpha (ERα) is localized to the plasma membrane in response to estrogen or by interaction with adaptor proteins like Shc and p130Cas [39, 40] . Therefore, the signaling pathway of estrogen receptor activation leading to increased TRPM6 activity needs to be further investigated.
Interestingly, a disturbed Mg 2+ balance has also been correlated with insulin resistance and type 2 diabetes. Diabetes is associated with renal Mg 2+ wasting, but the responsible molecular mechanism is unknown. Streptozotocin (STZ)-induced diabetic rats display an increased renal TRPM6 mRNA expression, which may represent a compensatory mechanism for the increased Mg 2+ load to the DCT, the renal segment of active Mg 2+ reabsorption. Furthermore, insulin administration reversed this increased abundance in TRPM6 and corrected the hypermagnesiuria observed in these rats [41] . Recently, suggestive evidence has been provided that two common TRPM6 genetic variants (I1393V and K1584E polymorphisms) are associated with an increased risk of type 2 diabetes in women with low Mg 2+ intake [42] . Unraveling the role of these hormones in TRPM6 regulation might shed new light on the understanding of active Mg 2+ (re)absorption.
Other regulatory factors
The expression level of TRPM6 is tightly regulated by dietary Mg
2+
. Mice fed a diet deficient in Mg
showed increased renal TRPM6 mRNA and protein expression, whereas a Mg 2+ -enriched diet upregulated TRPM6 mRNA levels in the colon [34] . Additionally, long-term treatment with the immunosuppressive agent tacrolimus was shown to induce hypomagnesemia, which can be explained by a downregulation of renal TRPM6 expression [43] . In line with this, Ikari et al. [44] demonstrated decreased TRPM6 expression by cyclosporin A in a dosedependent manner. Next to this drug-induced hypomagnesemia, chronic metabolic acidosis can decrease the renal TRPM6 expression and result in Mg 2+ wasting, whereas chronic metabolic alkalosis has the converse effect [45] . Hypomagnesemia has also been observed in patients with Gitelman's syndrome, caused by mutations in the thiazide-sensitive Na + /Cl -co-transporter (NCC) [46, 47] . Inhibition of NCC by thiazide diuretics has been reported to downregulate TRPM6 expression, which provides an explanation for the Mg 2+ wasting. It is, however, unclear how the absence of NCC activity signals to decrease TRPM6 abundance [48] . These studies support the role of TRPM6 in Mg 2+ homeostasis and implicate the channel in pharmacological therapeutics.
Conclusion

TRPM6 plays a central role in Mg
2+ homeostasis as the apical entry pathway in both the colon and DCT. This review highlights the newest findings in the molecular regulation of TRPM6 (figure 1). The identification of the regulatory factors of the α-kinase domain has advanced our knowledge on the control of TRPM6 activity. Moreover, understanding the regulation of TRPM6 activity in a short time scale has been improved by unraveling the signaling pathway of EGFR activation and the finding of estrogen stimulation on TRPM6. Further investigation into the hormonal control of TRPM6 trafficking and activity will provide more detail for our understanding of the body's Mg 2+ balance. In addition, little experimental evidence is available on the cellular diffusion and basolateral extrusion of Mg 2+ . Future studies of families with rare inherited forms of renal hypomagnesemia will help to elucidate novel genes and the molecular mechanisms in active Mg 2+ reabsorption.
